xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®
Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment OAKLAND, CALIFORNIA, UNITED STATES, March 10, 2022 /EINPresswire.com/ -- Today, xCures …